1. Warren MD, Miller AM, Traylor J, et al. Implementation of a statewide surveillance system for neonatal abstinence syndrome. MMWR Morb Mortal Wkly Rep 2015;64:125–128.
2. Olsen M, Breuel K, Alexander C. High prevalence of buprenorphine in prenatal drug screens in an Appalachian city. South Med J 2020;113:111–115.
3. Bell J, Towers CV, Hennessy MD, et al. Detoxification from opiate drugs uring pregnancy. Am J Obstet Gynecol 2016;215:374.e1–374.e6.
4. Dashe JS, Jackson GL, Olscher DA, et al. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92:854–858.
5. Luty J, Nikolaou V, Beam J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003;24:363–367.
6. Stewart RD, Nelson DB, Adhikari EH, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol 2013;209:267.e1–267.e5.
7. Lund IO, Fitzsimons H, Tuten M, et al. Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse Rehabil 2012;3(suppl 1):17–25.
8. Wang MJ, Kuper SG, Sims B, et al. Opioid detoxification in pregnancy: systematic review and meta-analysis of perinatal outcomes. Am J Perinatol 2019;36:581–587.
9. Armstrong MA, Gonzales OV, Lieberman L, et al. Perinatal substance abuse intervention in obstetric clinics decreases adverse neonatal outcomes. J Perinatol 200;23:3–9.
10. Goler NC, Armstrong MA, Taillac CJ, et al. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard. J Perinatol 2008;28:597–603.
11. Tennessee Department of Health. Neonatal abstinence syndrome surveillance: May 2019 update (data through 06/01/2019). https://www.tn.gov/content/dam/tn/health/documents/nas/May_2019__NAS_Monthly_Update.pdf
. Accessed February 21, 2020.
12. Bianchi DW, Gillman MW. Addressing the impact of opioids on women and children. Am J Obstet Gynecol 2019;221:123.E1–123.E4.
13. Terplan M, Laird HJ, Hand DJ, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol 2018;131:803–814.
14. Centers for Medicare & Medicaid Services. Opioid oral morphine milligram equivalent (MME) conversion factors. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCOvCOntra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-Aug-2017.pdf
. Accessed October 23, 2019.
15. Committee on Obstetric Practice, American Society of Addiction Medicine. Opioid use and opioid use disorder in pregnancy Committee Opinion Number 711. Obstet Gynecol 2017;130:e81–e94.
16. Treatment of morphine-type dependence by withdrawal methods. JAMA 1972;219:1611–1615.
17. Ecker J, Abuhamad A, Hill W, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol 2019;221:B5–B28.
18. Rementeria JL, Nunag NN. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol 1973;116:1152–1156.
19. Zuspan FP, Gumpel JA, Mejia-Zelay A, et al. Fetal stress from methadone withdrawal. Am J Obstet Gynecol 1975;122:43–46.
20. Towers CV, Terry P, Rackley B, et al. Fetal outcomes with detoxification from opioid drugs during pregnancy: a systematic review. Am J Perinatol 2020;37:679–688.
21. Haabrekke KJ, Slinning K, Walhovd KB, et al. The perinatal outcome of children born to women with substance dependence detoxified in residential treatment during pregnancy. J Addict Dis 2014;33:114–123.
22. Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012;107(suppl 1):5–27.
23. Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006;126:170–175.
24. Oei JL, Melhuish E, Uebel H, et al. Neonatal abstinence syndrome and high school performance. Pediatrics 2017;139:e20162651.
25. Fill MA, Miller AM, Wilkinson RH, et al. Educational disabilities among children born with neonatal abstinence syndrome. Pediatrics 2018;142:e20180562.
26. Hunt RW, Tzioumi D, Collins E, et al. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008;84:29–35.
27. Davis DD, Templer DI. Neurobehavioral functioning in children exposed to narcotics in utero. Addict Behav 1988;13:275–283.
28. Sundelin Wahlsten V, Sarman I. Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediatr 2013;102:544–549.
29. Caritis SN, Panigrahy A. Opioids affect the fetal brain: reframing the detoxification debate. Am J Obstet Gynecol 2019;221:602–608.
30. Brogly SB, Saia KE, Werler MM, et al. Prenatal treatment and outcomes of women with opioid use disorder. Obstet Gynecol 2018;132:916–922.
31. Howland RH. A question about the safety of buprenorphine/naloxone and benzodiazepine drugs. J Psychosoc Nurs Ment Health Serv 2015;53:11–14.
32. Paone D, Tuazon E, Stajic M, et al. Buprenorphine infrequently found in fatal overdose in New York City. Drug Alcohol Depend 2015;155:298–301.
33. Walker JJ, Olsen ME. Provision of buprenorphine to pregnant women by for-profit clinics in an Appalachian city. South Med J 2018;111:575–578.
34. O’Connor AB, O’Brien L, Alto WA. Maternal buprenorphine dose at delivery and its relationship to neonatal outcomes. Eur Addict Res 2016;22:127–130.
35. Jones HE, Dengler E, Garrison A, et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. DrugAlcohol Depend 2014;134:414–417.
36. Dooley R, Dooley J, Antone I, et al. Narcotic tapering in pregnancy using long-acting morphine: an 18-month prospective cohort study in northwestern Ontario. Can Fam Physician 2015;61:e88–e95.